COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS

6 Months Ended

Jun. 30, 2016

COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS [Abstract]

COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS

NOTE 3 — COLLABORATIVE RESEARCH AND DEVELOPMENT ARRANGEMENTS:

RVR DPP® technology transfer agreement:

In February 2014, the Company entered into a technology transfer agreement with RVR Diagnostics for $1,500,000. The agreement was modified in September 2014. The Company did not earn revenues during the six-month periods ended June 30, 2016 and 2015, respectively from this agreement. The Company earned $1,250,000 from this grant from inception through June 30, 2016.

Dengue agreement:

In October 2014, the Company entered into a technology development agreement with a diagnostics company for $300,000. The Company earned $- and $140,000 for the six-month periods ended June 30, 2016 and 2015, respectively from this agreement. The Company earned $300,000 from this grant from inception through June 30, 2016 and the development is completed.

Brain Injury agreement:

In January 2015, the Company entered into a technology development agreement with Perseus Science Group LLC for $946,000. The Company earned $188,098 and $252,500 for the six-month periods ended June 30, 2016 and 2015, respectively from this agreement. The Company earned $657,716 from this grant from inception through June 30, 2016.

Malaria agreements:

In January 2015, the Company was awarded a grant from the Bill & Melinda Gates Foundation for $307,000. The Company earned $- and $258,900 for the six-month periods ended June 30, 2016 and 2015, respectively from this agreement. The Company earned $307,000 from this grant from inception through June 30, 2016 and the development is completed.

In April 2016, the Company was awarded a grant from the Bill & Melinda Gates Foundation for $678,000. The Company earned $25,866 for the six-month periods ended June 30, 2016 from this agreement. The Company earned $25,866 from this grant from inception through June 30, 2016.

Cancer agreement:

In October 2014, the Company entered into a technology development agreement with an international diagnostics company for $320,000. The Company earned $50,000 and $75,000 for the six-month periods ended June 30, 2016 and 2015, respectively from this agreement. The Company earned $255,000 from this grant from inception through June 30, 2016.

Fever Panel agreement:

In October 2015, the Company entered into a technology development agreement with the Paul G. Allen Ebola Program for $2,118,000 and a follow-on agreement in February 2016 for $550,000. The Company earned $1,559,500 and $- for the six-month periods ended June 30, 2016 and 2015, respectively from this agreement. The Company earned $1,968,000 from this grant from inception through June 30, 2016.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details